Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Repare Therapeutics ( ($RPTX) ) has issued an announcement. Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six ...

Context for Gilead Sciences stock today Gilead Sciences (GILD) is in focus for investors after recent share price moves, with ...

Shares of Gilead Sciences Inc. GILD shed 2.96% to $120.67 Thursday, on what proved to be an all-around favorable trading ...

A Gilead Sciences executive who left the San Fransisco pharmaceutical giant last month after nearly four years, has been ...

Gilead Sciences advances global biopharmaceutical research as companies within the nasdaq 100 index shape healthcare ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company ...